Novo Nordisk Expects 2026 Adjusted Sales Growth Between -5% To -13% At CER

Reuters02-04

Feb 3 (Reuters) - Novo Nordisk A/S ::
*NOVO NORDISK RELEASES 2026 SALES AND OPERATING PROFIT OUTLOOK
*NOVO NORDISK - 2026 PROFIT IMPACTED BY USD 4.2 BILLION REVERSAL
*NOVO NORDISK - TO EXPAND WEGOVY ROLL-OUT IN 2026
*NOVO NORDISK - 2026 ADJUSTED SALES GROWTH EXPECTED -5% TO -13% AT CER
*NOVO NORDISK - SALES UP 10%, OPERATING PROFIT UP 6% IN 2025
*NOVO NORDISK OUTLOOK 2026 ADJUSTED OPERATING PROFIT GROWTH IS EXPECTED TO BE -5% TO -13% AT CER
*NOVO NORDISK: EXPECTS TO INTRODUCE WEGOVY 7.2MG DOSE IN A NUMBER OF COUNTRIES IN 2026

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 03-FEB-202616:37:17.07 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608806853?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 00:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608806853","market":"fut","top_or_hot":-1,"title":"Novo Nordisk Expects 2026 Adjusted Sales Growth Between -5% To -13% At CER","media":"Reuters","content":"<html><body>Feb 3 (Reuters) - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> A/S <novob.co>::<br/>*NOVO NORDISK RELEASES 2026 SALES AND OPERATING PROFIT OUTLOOK<br/>*NOVO NORDISK - 2026 PROFIT IMPACTED BY USD 4.2 BILLION REVERSAL<br/>*NOVO NORDISK - TO EXPAND WEGOVY ROLL-OUT IN 2026<br/>*NOVO NORDISK - 2026 ADJUSTED SALES GROWTH EXPECTED -5% TO -13% AT CER<br/>*NOVO NORDISK - SALES UP 10%, OPERATING PROFIT UP 6% IN 2025<br/>*NOVO NORDISK OUTLOOK 2026 ADJUSTED OPERATING PROFIT GROWTH IS EXPECTED TO BE -5% TO -13% AT CER<br/>*NOVO NORDISK: EXPECTS TO INTRODUCE WEGOVY 7.2MG DOSE IN A NUMBER OF COUNTRIES IN 2026<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 03-FEB-202616:37:17.07 GMT</novob.co></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Expects 2026 Adjusted Sales Growth Between -5% To -13% At CER</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Expects 2026 Adjusted Sales Growth Between -5% To -13% At CER\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-04 00:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Feb 3 (Reuters) - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> A/S <novob.co>::<br/>*NOVO NORDISK RELEASES 2026 SALES AND OPERATING PROFIT OUTLOOK<br/>*NOVO NORDISK - 2026 PROFIT IMPACTED BY USD 4.2 BILLION REVERSAL<br/>*NOVO NORDISK - TO EXPAND WEGOVY ROLL-OUT IN 2026<br/>*NOVO NORDISK - 2026 ADJUSTED SALES GROWTH EXPECTED -5% TO -13% AT CER<br/>*NOVO NORDISK - SALES UP 10%, OPERATING PROFIT UP 6% IN 2025<br/>*NOVO NORDISK OUTLOOK 2026 ADJUSTED OPERATING PROFIT GROWTH IS EXPECTED TO BE -5% TO -13% AT CER<br/>*NOVO NORDISK: EXPECTS TO INTRODUCE WEGOVY 7.2MG DOSE IN A NUMBER OF COUNTRIES IN 2026<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 03-FEB-202616:37:17.07 GMT</novob.co></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nRSD8SJGY0:1","article_id":"2608806853","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608806853","pubTimestamp":1770137990,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Feb 3 (Reuters) - Novo Nordisk A/S ::*NOVO NORDISK RELEASES 2026 SALES AND OPERATING PROFIT OUTLOOK*NOVO NORDISK - 2026 PROFIT IMPACTED BY USD 4.2 BILLION REVERSAL*NOVO NORDISK - TO EXPAND WEGOVY ROLL","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"诺和诺德预计2026年调整后销售额按CER计算增长在-5%至-13%之间","themeId":"bcb73b9a2718796b6bdfcc143da1014d","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{},"content_text":"Feb 3 (Reuters) - Novo Nordisk A/S ::*NOVO NORDISK RELEASES 2026 SALES AND OPERATING PROFIT OUTLOOK*NOVO NORDISK - 2026 PROFIT IMPACTED BY USD 4.2 BILLION REVERSAL*NOVO NORDISK - TO EXPAND WEGOVY ROLL-OUT IN 2026*NOVO NORDISK - 2026 ADJUSTED SALES GROWTH EXPECTED -5% TO -13% AT CER*NOVO NORDISK - SALES UP 10%, OPERATING PROFIT UP 6% IN 2025*NOVO NORDISK OUTLOOK 2026 ADJUSTED OPERATING PROFIT GROWTH IS EXPECTED TO BE -5% TO -13% AT CER*NOVO NORDISK: EXPECTS TO INTRODUCE WEGOVY 7.2MG DOSE IN A NUMBER OF COUNTRIES IN 2026  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 03-FEB-202616:37:17.07 GMT","kind":"highlight","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608806853","isCrawlerRequest":true}